404 related articles for article (PubMed ID: 27786552)
21. Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R; McShane R; Lindesay J; Ritchie C; Baldwin A; Barber R; Burns A; Dening T; Findlay D; Holmes C; Hughes A; Jacoby R; Jones R; Jones R; McKeith I; Macharouthu A; O'Brien J; Passmore P; Sheehan B; Juszczak E; Katona C; Hills R; Knapp M; Ballard C; Brown R; Banerjee S; Onions C; Griffin M; Adams J; Gray R; Johnson T; Bentham P; Phillips P
N Engl J Med; 2012 Mar; 366(10):893-903. PubMed ID: 22397651
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Olazarán J; Carnero-Pardo C; Fortea J; Sánchez-Juan P; García-Ribas G; Viñuela F; Martínez-Lage P; Boada M
Alzheimers Res Ther; 2023 Aug; 15(1):130. PubMed ID: 37537656
[TBL] [Abstract][Full Text] [Related]
23. Evidence-based pharmacotherapy of Alzheimer's disease.
Evans JG; Wilcock G; Birks J
Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
[TBL] [Abstract][Full Text] [Related]
24. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S
Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacotherapy for Alzheimer's disease].
Verhey FR
Tijdschr Psychiatr; 2006; 48(1):17-26. PubMed ID: 16955982
[TBL] [Abstract][Full Text] [Related]
26. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
Grossberg GT; Edwards KR; Zhao Q
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
[TBL] [Abstract][Full Text] [Related]
27. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
Ritchie CW; Ames D; Clayton T; Lai R
Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273
[TBL] [Abstract][Full Text] [Related]
28. Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
van Dyck CH
CNS Spectr; 2004 Jul; 9(7 Suppl 5):24-8. PubMed ID: 15241297
[TBL] [Abstract][Full Text] [Related]
29. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
[TBL] [Abstract][Full Text] [Related]
30. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Thompson S; Lanctôt KL; Herrmann N
Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
[TBL] [Abstract][Full Text] [Related]
31. [Current approaches to optimize treatment of dementia and Alzheimer's disease].
Kolykhalov IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):87-92. PubMed ID: 28635795
[TBL] [Abstract][Full Text] [Related]
32. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP
Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502
[TBL] [Abstract][Full Text] [Related]
33. Alzheimer Disease: Monotherapy vs. Combination Therapy.
Lawler E; Avila A
Am Fam Physician; 2017 Apr; 95(7):452. PubMed ID: 28409590
[No Abstract] [Full Text] [Related]
34. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
[TBL] [Abstract][Full Text] [Related]
35. Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
Prescrire Int; 2011 Apr; 20(115):95. PubMed ID: 21648211
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M; Eap CB
Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
[TBL] [Abstract][Full Text] [Related]
37. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
Mohammad D; Chan P; Bradley J; Lanctôt K; Herrmann N
Expert Opin Drug Saf; 2017 Sep; 16(9):1009-1019. PubMed ID: 28678552
[TBL] [Abstract][Full Text] [Related]
38. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
39. Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
Matsuzono K; Yamashita T; Ohta Y; Hishikawa N; Sato K; Kono S; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 46(3):687-93. PubMed ID: 26402513
[TBL] [Abstract][Full Text] [Related]
40. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.
Repantis D; Laisney O; Heuser I
Pharmacol Res; 2010 Jun; 61(6):473-81. PubMed ID: 20193764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]